Table 2. Univariate analysis of potential predictors for prognosis of HC patients.

Item	n	Median of survival time (month)		OS rate(%)	p
Age	<60 years	97	41.1	34.0%	0.983
	≥60 years	84	41.3	33.3%
Sex	Male	103	41.0	34.0%	0.953
	Female	78	41.5	33.3%
Tumor size	<2.5 cm	114	42.4	36.0%	0.320
	≥2.5 cm	67	39.3	29.9%
Differentiation	High and moderate	174	42.1	33.9%	0.060
	Poor	7	20.7	28.6%
Bismuth-Corlette classification	I+II	42	48.2	45.2%	0.036
	IIIa+IIIb+IV	139	39.1	30.2%
Lymph node metastasis	Negative	117	45.0	37.8%	0.007
	Positive	64	33.9	25.8%
Nerve invasion	Negative	109	42.3	38.5%	0.134
	Positive	72	39.6	26.4%
Portal vein invasion	Negative	126	42.9	38.1%	0.027
	Positive	55	37.4	23.6%
Hepatic artery invasion	Negative	142	42.5	37.3%	0.019
	Positive	39	36.4	20.5%
Liver invasion	Negative	132	44.0	35.6%	0.030
	Positive	49	33.8	28.6%
Incised margin	Negative(R0)	151	43.5	37.1%	0.001
	Positive(R1)	30	29.6	16.7%
Total bilirubin	<100 mg/L	77	40.7	35.1%	0.868
	≥100 mg/L	104	41.6	32.7%
Preoperative biliary drainage	Undone	126	42.8	38.9%	0.026
	Done	55	37.6	21.8%
Postoperative radiotherapy	Undone	109	40.9	33.0%	0.825
	Done	72	41.8	34.7%
MMP-9	<201.93 ng/mL	75	50.9	69.3%	<0.001
	≥201.93 ng/mL	106	34.5	8.5%

Note: OS: overall survival; MMP-9: matrix metalloproteinase-9.